Q: 'Plasma exchange' in Lambert-Eaton myasthenic syndrome is considered a Category I indication.
A) Yes
B) False
Answer: B
The objective of this question is to familiarize students with the academic basis of therapeutic categories of Plasma Exchange (PE), a broadly described term for different categories of Apheresis. The American Society for Apheresis (ASFA) systematically describes these categories to prevent abuse of this high-risk procedure.
Category I – first-line therapy, either as primary stand-alone treatment or in conjunction with other modes of treatment. Classic examples
- immune TTP
- acute inflammatory demyelinating polyradiculoneuropathy
- sickle cell disease with certain complications such as stroke
Category II – apheresis is accepted "as second-line therapy," either as a stand-alone treatment or in conjunction with other treatments. Examples are
- life-threatening hemolytic anemia for cold agglutinin disease
- Lambert-Eaton myasthenic syndrome (see above question)
Category III – optimum role of apheresis therapy is not established.
- hypertriglyceridemic pancreatitis
- extracorporeal photopheresis for nephrogenic systemic fibrosis
Category IV – evidence suggests apheresis may be ineffective or harmful. AFSA recommends approval from either hospital's IRB or equivalent committee. Examples:
- certain drug-induced thrombotic microangiopathies
*AFSA documents most of the PE-required disease processes under each category for clinicians to refer to.
#procedures
#hematology
References:
1. Connelly-Smith L, Alquist CR, Aqui NA, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. J Clin Apher 2023; 38:77.
2. Kaplan AA. Therapeutic plasma exchange: core curriculum 2008. Am J Kidney Dis 2008; 52:1180.
No comments:
Post a Comment